AVROBIO Past Earnings Performance
Past criteria checks 2/6
AVROBIO has been growing earnings at an average annual rate of 5%, while the Biotechs industry saw earnings growing at 14.5% annually.
Key information
5.0%
Earnings growth rate
19.4%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | 12.8% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK
Oct 18Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status
Sep 20AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy
Jul 13Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation
Nov 13We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate
Aug 10AVROBIO: Fabrazyme's Full Approval Changes Things
May 05Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation
Mar 08AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise
Dec 25We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth
Nov 23AVROBIO readies $75M equity offering
Nov 19AVROBIO EPS misses by $0.19
Nov 05Revenue & Expenses BreakdownBeta
How AVROBIO makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | 12 | 23 | 44 |
30 Sep 23 | 0 | -4 | 26 | 61 |
30 Jun 23 | 0 | -5 | 27 | 63 |
31 Mar 23 | 0 | -101 | 31 | 70 |
31 Dec 22 | 0 | -106 | 33 | 72 |
30 Sep 22 | 0 | -109 | 35 | 73 |
30 Jun 22 | 0 | -119 | 38 | 80 |
31 Mar 22 | 0 | -122 | 38 | 84 |
31 Dec 21 | 0 | -119 | 36 | 83 |
30 Sep 21 | 0 | -119 | 35 | 84 |
30 Jun 21 | 0 | -123 | 34 | 89 |
31 Mar 21 | 0 | -121 | 33 | 87 |
31 Dec 20 | 0 | -120 | 33 | 87 |
30 Sep 20 | 0 | -114 | 31 | 85 |
30 Jun 20 | 0 | -95 | 28 | 69 |
31 Mar 20 | 0 | -82 | 24 | 61 |
31 Dec 19 | 0 | -73 | 21 | 55 |
30 Sep 19 | 0 | -66 | 18 | 51 |
30 Jun 19 | 0 | -61 | 16 | 47 |
31 Mar 19 | 0 | -55 | 14 | 42 |
31 Dec 18 | 0 | -49 | 11 | 35 |
30 Sep 18 | 0 | -40 | 8 | 29 |
30 Jun 18 | 0 | -35 | 6 | 25 |
31 Mar 18 | 0 | -27 | 5 | 19 |
31 Dec 17 | 0 | -19 | 3 | 15 |
Quality Earnings: AVRO has a large one-off gain of $75.9M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: AVRO became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AVRO has become profitable over the past 5 years, growing earnings by 5% per year.
Accelerating Growth: AVRO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: AVRO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: AVRO's Return on Equity (12.8%) is considered low.